Previous 10 | Next 10 |
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...
DUBLIN , May 14, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that results from the Company's Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis will be the focus of an o...
As you may recall, in March I advised caution after Protagonist's ( PTGX ) strong run, as I suspected that the long delay of the IND filing for PTG-200 by its development partner Janssen might hide some problems. In addition, I had noticed a strong acceleration of the similar IBD collabora...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Theravance Biopharma, Inc. (TBPH) Q1 2019 Earnings Conference Call May 07, 2019 5:00 PM ET Company Participants Jessica Stitt - Vice President, Finance & Investor Relations Rick Winningham - Chief Executive Officer Brett Haumann - Chief Medical Officer Frank Pasqualone - Se...
Theravance Biopharma (NASDAQ: TBPH ): Q1 GAAP EPS of -$1.32 misses by $0.15 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , May 7, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter ended March 31, 2019 . Revenue for the first quarter of 2019 was $5.3 million . First quarter operating loss wa...
DUBLIN, Ireland , April 30, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesd...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with this Read more ...
DUBLIN, Ireland , April 2, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 9:20 a.m. ET . The conference w...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...